

(b) (4)



Sandostatin® LAR Depot
 (octreotide acetate) for injectable suspension,
 for gluteal intramuscular use



Rx only



NOVARTIS

10 mg
 For Intragluteal Injection
 NDC 0078-0811-81

ATTENTION:

There are 3 critical steps in the reconstitution of Sandostatin LAR. **Not following them could result in failure to deliver the drug adequately.**

- The injection kit must reach room temperature. Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
- After adding the diluent solution, ensure that the powder is fully saturated by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
- After saturation, shake the vial moderately in a horizontal direction for a minimum of 30 seconds until uniform suspension is formed.

Contents:

- One vial containing Sandostatin® LAR Depot
- One pre-filled syringe containing diluent solution for reconstitution
- One vial adapter for drug product reconstitution
- One 1.5" x 19 gauge safety injection needle

Sandostatin® LAR Depot
 (octreotide acetate) for injectable suspension,
 for gluteal intramuscular use

10 mg
 For Intragluteal Injection

If you have any questions about preparation and/or administration, please call 1-888-NOW-NOVA (1-888-693-6682).



0078-0811-81 1

ATTENTION:

There are 3 critical steps in the reconstitution of Sandostatin LAR. **Not following them could result in failure to deliver the drug adequately.**

- The injection kit must reach room temperature. Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
- After adding the diluent solution, ensure that the powder is fully saturated by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
- After saturation, shake the vial moderately in a horizontal direction for a minimum of 30 seconds until uniform suspension is formed.

Sandostatin® LAR Depot
 (octreotide acetate) for injectable suspension,
 for gluteal intramuscular use

10 mg
 For Intragluteal Injection

Each vial delivers:

octreotide acetate	11.2 mg*
*equivalent to 10 mg octreotide base	
inactive ingredients:	
D,L-lactic acid copolymer	188.8 mg
mamtilol	41.0 mg

STORAGE: Refrigerate at 2°C to 8°C (36°F to 46°F). Protect from light.

Rx only

Product of Switzerland.

Sandostatin® LAR Depot
 (octreotide acetate) for injectable suspension,
 for gluteal intramuscular use

10 mg
 For Intragluteal Injection

Sandostatin® LAR Depot
 (octreotide acetate) for injectable suspension,
 for gluteal intramuscular use

10 mg
 For Intragluteal Injection

Each diluent syringe contains:

Carboxymethylcellulose sodium	14 mg
mannitol	12 mg
poloxamer 188	4 mg
water for injection	2 mL

ATTENTION:

There are 3 critical steps in the reconstitution of Sandostatin LAR. **Not following them could result in failure to deliver the drug adequately.**

- The injection kit must reach room temperature. Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
- After adding the diluent solution, ensure that the powder is fully saturated by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
- After saturation, shake the vial moderately in a horizontal direction for a minimum of 30 seconds until uniform suspension is formed.

Diluent syringes are manufactured by:

Schering-Plough Animal Health Division
 Kenilworth, NJ 07033
 Switzerland, Austria
 Basel, Switzerland

Diluent syringes are manufactured by:

Abbott Biotectics B.V.
 Oost, The Netherlands

Distributed by:

Novartis Pharmaceuticals Corporation
 East Hanover, New Jersey 07936

© Novartis

Sandostatin® LAR Depot
 (octreotide acetate) for injectable suspension,
 for gluteal intramuscular use

10 mg
 For Intragluteal Injection

Sandostatin® LAR Depot
 (octreotide acetate) for injectable suspension,
 for gluteal intramuscular use

10 mg
 For Intragluteal Injection

NOVARTIS

Sandostatin® LAR Depot
 (octreotide acetate) for injectable suspension,
 for gluteal intramuscular use

10 mg
 For Intragluteal Injection

NOVARTIS

95 x 96 x 219

GTN
 EXP
 LOT
 SN

300017778 US

47358
 3086A1

(b) (4)

Sandostatin[®] LAR Depot
(octreotide acetate) for injectable suspension, **20 mg**
for gluteal intramuscular use

For Intragluteal Injection

47358
3086A1

300017800 US

ATTENTION:
There are 3 critical steps in the reconstitution of Sandostatin LAR. **Not** following them could result in failure to deliver the drug appropriately.
• The injection kit must reach room temperature. Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
• After adding the diluent solution, ensure that the powder is fully saturated by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
• After saturation, shake the vial moderately in a horizontal direction for a minimum of 30 seconds until uniform suspension is formed.

Each diluent syringe contains:
Carboxymethylcellulose sodium..... 14 mg
mannitol..... 12 mg
poloxamer 188..... 4 mg
water for injection..... 2 mL

Rx only

Product of Switzerland

For Intragluteal Injection

Sandostatin[®] LAR Depot
Vials are manufactured by:
Sandoz GmbH,
Schattenu, Austria
(Subsidiary of Novartis Pharma AG,
Basel, Switzerland)
Diluent syringes are manufactured by:
Abbott Biologicals B.V.
Ost, The Netherlands
Distributed by:
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936
© Novartis

300017800 US

Sandostatin[®] LAR Depot
(octreotide acetate) for injectable suspension, **20 mg**
for gluteal intramuscular use

NOVARTIS
For Intragluteal Injection

(b) (4)

Sandostatin[®] LAR Depot
(octreotide acetate) for injectable suspension, **20 mg**
for gluteal intramuscular use
For Intragluteal Injection

If you have any questions about preparation and/or administration,
please call 1-888-NOW-NOVA (1-888-668-6682).

0078-0818-81 0
N

Each vial delivers:
octreotide acetate..... 22.4 mg*
*equivalent to 20 mg octreotide base
inactive ingredients:
DL-lactic acid copolymer..... 377.6 mg
mannitol..... 81.9 mg

STORAGE: Refrigerate at 2°C to 8°C (36°F to 46°F). Protect from light.

Sandostatin[®] LAR Depot
(octreotide acetate) for injectable suspension,
for gluteal intramuscular use

ATTENTION:
There are 3 critical steps in the reconstitution of Sandostatin LAR. **Not** following them could result in failure to deliver the drug appropriately.
• The injection kit must reach room temperature. Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
• After adding the diluent solution, ensure that the powder is fully saturated by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
• After saturation, shake the vial moderately in a horizontal direction for a minimum of 30 seconds until uniform suspension is formed.

- Contents:**
- One vial containing Sandostatin[®] LAR Depot
 - One prefilled syringe containing diluent solution for reconstitution
 - One vial adapter for drug product reconstitution
 - One 1.5" x 19 gauge safety injection needle

20 mg
For Intragluteal Injection
NDC 0078-0818-81

ATTENTION:

- There are 3 critical steps in the reconstitution of Sandostatin LAR. **Not** following them could result in failure to deliver the drug appropriately.
• The injection kit must reach room temperature. Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
• After adding the diluent solution, ensure that the powder is fully saturated by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
• After saturation, shake the vial moderately in a horizontal direction for a minimum of 30 seconds until uniform suspension is formed.

Sandostatin[®] LAR Depot
(octreotide acetate) for injectable suspension,
for gluteal intramuscular use



Rx only

NOVARTIS

20

(b) (4)

95 x 38 x 219

GTIN
EXP
LOT
SN

(b) (4)

Sandostatin® LAR Depot
 (octreotide acetate) for injectable suspension,
 for gluteal intramuscular use

Rx only

NOVARTIS

30 mg

Rx only

NOVARTIS

Rx only

NOVARTIS

There are 3 critical steps in the reconstitution of Sandostatin LAR. Not following them could result in failure to deliver the drug appropriately.

- The injection kit must reach room temperature. Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
- After adding the diluent solution, ensure that the powder is fully saturated by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
- After saturation, shake the vial moderately in a horizontal direction for a minimum of 30 seconds until uniform suspension is formed.

ATTENTION:

- Contents:**
- One vial containing Sandostatin® LAR Depot
 - One prefilled syringe containing diluent solution for reconstitution
 - One vial adapter for drug product reconstitution
 - One 1.5" x 19 gauge safety injection needle

30 mg
 For Intragluteal Injection
 NDC 0078-0825-81

300017795 US

Sandostatin® LAR Depot
 (octreotide acetate) for injectable suspension, 30 mg
 for gluteal intramuscular use

30 mg
 For Intragluteal Injection

If you have any questions about preparation and/or administration, please call 1-888-NON-NOVA (1-888-669-6662).

8 1-8-2825-81
 0078-0825-81

ATTENTION:

There are 3 critical steps in the reconstitution of Sandostatin LAR. Not following them could result in failure to deliver the drug appropriately.

- The injection kit must reach room temperature. Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
- After adding the diluent solution, ensure that the powder is fully saturated by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
- After saturation, shake the vial moderately in a horizontal direction for a minimum of 30 seconds until uniform suspension is formed.

Each vial delivers:

octreotide acetate	33.6 mg*
*equivalent to 30 mg octreotide base	
Inactive ingredients:	
D,L-lactic acid and glycolic acid copolymer	566.4 mg
mannitol	122.9 mg

STORAGE: Refrigerate at 2°C to 8°C (36°F to 46°F). Protect from light.

For Intragluteal Injection

Sandostatin® LAR Depot
 (octreotide acetate) for injectable suspension,
 for gluteal intramuscular use

ATTENTION:

There are 3 critical steps in the reconstitution of Sandostatin LAR. Not following them could result in failure to deliver the drug appropriately.

- This injection kit must reach room temperature. Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
- After adding the diluent solution, ensure that the powder is fully saturated by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
- After saturation, shake the vial moderately in a horizontal direction for a minimum of 30 seconds until uniform suspension is formed.

Each diluent syringe contains:

Carboxymethylcellulose sodium	14 mg
mannitol	12 mg
poloxamer 188	4 mg
water for injection	2 mL

Rx only

For Intragluteal Injection

Sandostatin® LAR Depot
 Vials are manufactured by:
 Novartis GmbH, Austria
 (Subsidiary of Novartis Pharma AG,
 Basel, Switzerland)
 Diluent syringes are manufactured by:
 Abbott Biologicals B.V.
 Oost, The Netherlands
Distributed by:
 Novartis Pharmaceuticals Corporation
 East Hanover, New Jersey 07936
 © Novartis

Sandostatin® LAR Depot
 (octreotide acetate) for injectable suspension, 30 mg
 for gluteal intramuscular use

For Intragluteal Injection

47358
 3086A1

Sandostatin® LAR Depot
 (octreotide acetate) for injectable suspension,
 for gluteal intramuscular use

30 mg
 For Intragluteal Injection

30 mg
 For Intragluteal Injection

(b) (4)